Warburg Pincus picked Haihe Pharmaceutical as its first bet on innovative drug development in China, having been convinced by the company's mature portfolio and international expansion plans
Private investors have plowed more than $5.5 billion into Chinese biotech since 2017, a near sevenfold increase on the combined total for the preceding four years. Yet Warburg Pincus held its fire, waiting...
Increased climate change awareness on a corporate level is leading to more investment – either direct or through funds – in start-ups that offer mitigation solutions. Asia is a key geography
Healthcare-focused Panacea Venture has led a $40 million Series C round for China’s XWPharma, a neurobiology-focused biotech developer previously known as XW Laboratories.
Kyee Technology, a Chinese digital medical platform has raised RMB430 million ($64 million) in a Series D round led by Tencent Holdings. Other investors include Longmen Capital, Dyee Capital and Royal Sea Capital.
Biocytogen, a Chinese contract research organization (CRO) that provides genetically-modified mice for drug testing, has raised RMB970 million ($143 million) in an extended tranche of Series D funding.